US creates blame-free adverse event reporting

January 2006
CMAJ: Canadian Medical Association Journal;1/3/2006, Vol. 174 Issue 1, p19
Academic Journal
No abstract available.


Related Articles

  • Reporting Adverse Events in Gene Therapy Studies. Grilley, B.J.; Aguilar, L.K.; Aguilar-Cordova, E. // BioDrugs;2000, Vol. 14 Issue 3, p141 

    The reporting of adverse events occurring in gene therapy studies is currently under discussion. There are many agencies involved in the reporting of adverse events, often with reporting guidelines that are unique to each organisation. Guidelines differ according to the type of event (adverse...

  • CREATE A NO-BLAME CULTURE FOR A SAFER WORKPLACE. MANSON, KIM // MHD Supply Chain Solutions;Sep/Oct2015, Vol. 45 Issue 5, p24 

    The article ways to create a no-blame culture in the warehouse management and logistics sector. Topics covered include the importance of the blame-free culture in encouraging the reporting of accidental damage, the need for managers to accept reports positively without blaming the employee who...

  • FDA, NIH collaborate on AE reporting. J. G. D. // Medical Marketing & Media;Apr2008, Vol. 43 Issue 4, p16 

    The article reports on the Food and Drug Administration and the National Institutes of Health's joint development of a harmonized adverse event (AE) reporting mechanism in the U.S. It claims that both parties have jointly created a Federal Adverse Event Task Force which is specifically assigned...

  • Number for vaccine reactions available.  // Dermatology Times;Jul95, Vol. 16 Issue 7, p58 

    Reports that the US Department of Health has established a Vaccine Adverse Event Reporting System (VAERS) to accept reports of suspected adverse reactions to vaccines. Contact information.

  • Adverse Event Management During Clinical Investigations. Donawa, Maria // Medical Device Technology;Nov2002, Vol. 13 Issue 9, p36 

    Discusses amendments to adverse event definitions contained in a draft international standard for the documentation and evaluation of adverse events involving medical devices. Comparison of U.S. and European criteria for reporting serious adverse events; Methods for improving the process of...

  • Making the Most Of FDA's MedWatch. Abelson, Mark B.; Lafond, Ashley // Review of Ophthalmology;Jan2011, Vol. 18 Issue 1, p46 

    The article offers information about the MedWatch program created by David A. Kessler, the commissioner of the U.S. Food and Drug Administration. It states that the program is created to educate patients and healthcare providers on the significance of identifying and reporting adverse events and...

  • Report on active surveillance for adverse events following the use of drug co-administrations in the Global Programme to Eliminate Lymphatic Filariasis.  // Weekly Epidemiological Record;9/5/2003, Vol. 78 Issue 36, p315 

    Reports on the incidence of adverse events following the use of drug coadministrations to eliminate lymphatic filariasis. Type of adverse events; Severity of adverse events; Frequency of adverse events.

  • fda.gov. Henkel, John // FDA Consumer;Mar/Apr2002, Vol. 36 Issue 2, p37 

    Presents updates on the Web sites of the U.S. Food and Drug Administration and other government agencies in the U.S. Information on FirstGov for Consumers; Objective of the program called the Vaccine Adverse Event Reporting System; Function of the Web site Disability Direct, created by the U.S....

  • Drug Safety and Shortages Challenge Manufacturers. Wechsler, Jill // BioPharm International;Mar2011, Vol. 24 Issue 3, p12 

    The article focuses on the goal of the Food & Drug Administration (FDA) to detect adverse drug events in the U.S. The FDA has created the adverse-event reports and databases to be able to avoid unsafe therapies. Moreover, the Mini-Sentinel pilot program was created to tap into the drug-use...

  • Why Were NIH Adverse Event Reporting Guidelines Misunderstood? Finn, Robert // JNCI: Journal of the National Cancer Institute;05/17/2000, Vol. 92 Issue 10, p784 

    Looks at the widespread confusion among investigators regarding adverse event reporting in the United States (US). Claims of unreported serious adverse events (SAE) in some clinical trials; Actions taken by the US National Institutes of Health and the US Food and Drug Administration to simplify...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics